Exploration on rationalization of diagnosis and treatment of breast cancer patients combined with COVID-19

doi:10.3969/j.issn.1674-8115.2022.12.013

Abstract

Abstract:

Coronavirus disease 2019 (COVID-19) has become a major global public health event as a new acute respiratory infectious disease. During the COVID-19 pandemic, compared with the healthy population, cancer patients had a higher risk of developing comorbidities of other systems, due to their bad poor immunity and older age. Research showed that breast cancer, as a malignant disease, had the highest disease incidence in female patients. Breast cancer patients with COVID-19 infection often have worse prognosis, and they have to postpone anti-tumor treatment due to COVID-19 infection. At present, the effect of delayed treatment on the survival rate of breast cancer patients is unclear, and whether the treatment plan of these patients should be adjusted is still being studied. Through the systematic review of existing clinical research studies, the guidelines of various societies and the expert consensus, this paper reviews the selection and rationalization of breast cancer treatment options under the COVID-19 epidemic, and discusses the opportunity and approaches of anti-tumor treatment for breast cancer patients infected with COVID-19.

Key words: breast cancer, coronavirus disease 2019 (COVID-19), surgery, radiotherapy, systemic therapy

CLC Number:

R737.9

ZHANG Yutang, JIN Yijie, ZHANG Fengchun, XU Yingchun. Exploration on rationalization of diagnosis and treatment of breast cancer patients combined with COVID-19[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2022, 42(12): 1745-1750.

Figures/Tables 1

TrendMD

References 32

1	LIANG W H, GUAN W J, CHEN R C, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China[J]. Lancet Oncol, 2020, 21(3): 335-337.
2	TIAN J, YUAN X, XIAO J, et al. Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre,
3	YU J, OUYANG W, CHUA M L K, et al. SARS-CoV-2 transmission in patients with cancer at a tertiary care hospital in Wuhan, China[J]. JAMA Oncol, 2020, 6(7): 1108-1110.
4	ZHANG L, ZHU F, XIE L, et al. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China[J]. Ann Oncol, 2020, 31(7): 894-901.
5	DAI M Y, LIU D B, LIU M, et al. Patients with cancer appear more vulnerable to SARS-CoV-2: a multicenter study during the COVID-19 outbreak[J]. Cancer Discov, 2020, 10(6): 783-791.
6	FOX T A, TROY-BARNES E, KIRKWOOD A A, et al. Clinical outcomes and risk factors for severe COVID-19 in patients with haematological disorders receiving chemo-or immunotherapy[J]. Br J Haematol, 2020, 191(2): 194-206.
7	LEE L Y, CAZIER J B, ANGELIS V, et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study[J]. Lancet, 2020, 395(10241): 1919-1926.
8	PATHANIA A S, PRATHIPATI P, ABDUL B A, et al. COVID-19 and cancer comorbidity: therapeutic opportunities and challenges[J]. Theranostics, 2021, 11(2): 731-753.
9	JEE J, FOOTE M B, LUMISH M, et al. Chemotherapy and COVID-19 outcomes in patients with cancer[J]. J Clin Oncol, 2020, 38(30): 3538-3546.
10	ROBILOTTI E V, BABADY N E, MEAD P A, et al. Determinants of COVID-19 disease severity in patients with cancer[J]. Nat Med, 2020, 26(8): 1218-1223.
11	DE AZAMBUJA E, TRAPANI D, LOIBL S, et al. ESMO management and treatment adapted recommendations in the COVID-19 era: breast cancer[J]. ESMO Open, 2020, 5(Suppl 3): e000793.
12	黎立喜, 马飞. 《新型冠状病毒肺炎疫情期间乳腺癌合理化诊疗指南》解读[J]. 中国肿瘤临床, 2020, 47(8): 379-383.
	LI L X, MA F. Interpretation of guidelines for the diagnosis and treatment of breast cancer during the COVID-19 outbreak[J]. Chin J Clin Oncol, 2020, 47(8): 379-383.
13	MARTA G N, POORTMANS P. Moderately hypofractionated breast radiation therapy: is more evidence needed? [J]. Lancet Oncol, 2019, 20(5): e226.
14	GRADISHAR W J, ANDERSON B O, ABRAHAM J, et al. Breast cancer, version 3.2020, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2020, 18(4): 452-478.
15	WANG S L, FANG H, SONG Y W, et al. Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: a randomised, non-inferiority, open-label, phase 3 trial[J]. Lancet Oncol, 2019, 20(3): 352-360.
16	CURIGLIANO G, BANERJEE S, CERVANTES A, et al. Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus[J]. Ann Oncol, 2020, 31(10): 1320-1335.
17	SULLIVAN R J, JOHNSON D B, RINI B I, et al. COVID-19 and immune checkpoint inhibitors: initial considerations[J]. J Immunother Cancer, 2020, 8(1): e000933.
18	DEEKS J J, DINNES J, TAKWOINGI Y, et al. Antibody tests for identification of current and past infection with SARS-CoV-2[J]. Cochrane Database Syst Rev, 2020, 6(6): CD013652.
19	VAN KAMPEN J J A, VAN DE VIJVER D A M C, FRAAIJ P L A, et al. Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19)[J]. Nat Commun, 2021, 12(1): 267.
20	RHEE C, KANJILAL S, BAKER M, et al. Duration of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectivity: when is it safe to discontinue isolation? [J]. Clin Infect Dis, 2021, 72(8): 1467-1474.
21	BULLARD J, DUST K, FUNK D, et al. Predicting infectious severe acute respiratory syndrome coronavirus 2 from diagnostic samples[J]. Clin Infect Dis, 2020, 71(10): 2663-2666.
22	YU K D, FAN L, QIU L X, et al. Influence of delayed initiation of adjuvant chemotherapy on breast cancer survival is subtype-dependent[J]. Oncotarget, 2017, 8(28): 46549-46556.
23	胡夕春, 胡志皇, 王碧芸, 等. 新型冠状病毒肺炎与抗肿瘤药物治疗[J]. 中国癌症杂志, 2022, 32(6): 499-511.
	HU X C, HU Z H, WANG B Y, et al. COVID-19 and systemic anti-cancer therapy[J]. Chin Oncol, 2022, 32(6): 499-511.
24	WEI J L, WU M J, LIU J, et al. Characteristics and outcomes of COVID-19 infection in 45 patients with breast cancer: a multi-center retrospective study in Hubei, China[J]. Breast, 2021, 59: 102-109.
25	BERSANELLI M. Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors[J]. Immunotherapy, 2020, 12(5): 269-273.
26	WU Q J, CHU Q, ZHANG H Y, et al. Clinical outcomes of coronavirus disease 2019 (COVID-19) in cancer patients with prior exposure to immune checkpoint inhibitors[J]. Cancer Commun (Lond), 2020, 40(8): 374-379.
27	LUO J, RIZVI H, EGGER J V, et al. Impact of PD-1 blockade on severity of COVID-19 in patients with lung cancers[J]. Cancer Discov, 2020, 10(8): 1121-1128.
28	LIÈVRE A, TURPIN A, RAY-COQUARD I, et al. Risk factors for coronavirus disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: a French nationwide cohort study (GCO-002 CACOVID-19)[J]. Eur J Cancer, 2020, 141: 62-81.
29	WANG B, HUANG Y. Immunotherapy or other anti-cancer treatments and risk of exacerbation and mortality in cancer patients with COVID-19: a systematic review and meta-analysis[J]. Oncoimmunology, 2020, 9(1): 1824646.
30	DI GIACOMO A M, GAMBALE E, MONTERISI S, et al. SARS-COV-2 infection in patients with cancer undergoing checkpoint blockade: clinical course and outcome[J]. Eur J Cancer, 2020, 133: 1-3.
31	HU S Y, YIN F Y, NIE L T, et al. Estrogen and estrogen receptor modulators: potential therapeutic strategies for COVID-19 and breast cancer[J]. Front Endocrinol (Lausanne), 2022, 13: 829879.
32	SAINI K S, LANZA C, ROMANO M, et al. Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathy[J]. Br J Cancer, 2020, 123(5): 694-697.

Type of therapy	Name of drug	Mechanism	NCT number
Chemotherapy	Methotrexate	Antimetabolite， DHFR inhibitor	NCT04352465
Target therapy	Palbociclib， abivertinib	CDK4/6 inhibitor	NCT05371275 NCT04440007
Immunotherapy	Nivolumab， pembrolizumab	PD-1inhibitor	NCT04356508 NCT04335305
Antiangiogenic therapy	Bevacizumab， nintedanib	VEGF inhibitor	NCT04275414 NCT04338802
Radiotherapy	/	Destroy DNA	NCT04366791

Type of therapy	Name of drug	Mechanism	NCT number
Chemotherapy	Methotrexate	Antimetabolite， DHFR inhibitor	NCT04352465
Target therapy	Palbociclib， abivertinib	CDK4/6 inhibitor	NCT05371275 NCT04440007
Immunotherapy	Nivolumab， pembrolizumab	PD-1inhibitor	NCT04356508 NCT04335305
Antiangiogenic therapy	Bevacizumab， nintedanib	VEGF inhibitor	NCT04275414 NCT04338802
Radiotherapy	/	Destroy DNA	NCT04366791

[1]	QIU Weiliu. Facing the trends of “Double First-Class” initiative, enhancing the construction of top disciplines: some thoughts on the construction of oral and maxillofacial surgery in Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2022, 42(9): 1163-1170.
[2]	SUN Huihua, TIAN Qiuju, WU Beiwen. Comparative study of different pneumoperitoneum modes on lower extremity deep venous blood flow velocity in patients undergoing laparoscopic surgery [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2022, 42(9): 1329-1335.
[3]	HUI Wenyu, WU Jinyang, HUANG Jianhua, LUAN Nan, ZHANG Zhiyuan, ZHANG Shilei. Experimental study on the accuracy evaluation of robot-assisted osteotomy of genioplasty [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2022, 42(9): 1347-1352.
[4]	TAO Baoxin, LAN Kengliang, HUANG Wei, WANG Feng, SHEN Yihan, WU Yiqun. Accuracy of dental implant placement in fully edentulous patients using a dynamic navigation system [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2022, 42(9): 1353-1360.
[5]	YAO Haoyi, LIU Yun, QIN Kaijie, ZHOU Mi, WANG Zhe, CHEN Anqing, ZHAO Qiang, LI Haiqing. Surgical treatment of moderate ischemic mitral regurgitation complicated with reduced left ventricular ejection fraction [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2022, 42(5): 629-634.
[6]	XIA Kunjian, DENG Linlin, WANG Lin. Construction and evaluation of a prediction model for liver injury induced by chemotherapy for breast cancer [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2022, 42(4): 502-509.
[7]	SU Juncheng, WANG Yuzheng, TANG Lei, XU Yingchun, ZHANG Fengchun. Clinical and pathological characteristics as well as prognostic analysis of breast cancer patients with brain metastases [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2022, 42(11): 1562-1568.
[8]	SUN Yameng, MA Ye, GUO Runsheng. Detection and analysis of copy number of HER2 gene in breast cancer tissue samples [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2022, 42(11): 1589-1597.
[9]	WANG Yuzheng, SU Juncheng, TANG Lei, XU Yingchun, ZHANG Fengchun. Weekly paclitaxel in combination with cisplatin in the first-line treatment of metastatic breast cancer: a retrospective study [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2022, 42(10): 1420-1427.
[10]	Ye HE, Fang FANG. Relationship between preoperative glycosylated hemoglobin and postoperative delirium in patients following off-pump coronary artery bypass grafting [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2022, 42(1): 21-27.
[11]	Cui CHEN, Ye JIN, Lin WANG, Hongli LI, Caifeng WAN, Lixin JIANG. Comparative analysis of 30 cases of metaplastic carcinoma of the breast [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2022, 42(1): 70-76.
[12]	Dewei QIAN, Ren ZHOU, Lichun GUAN, Hang ZHANG, Min YU. Meta-analysis of impacts of inhaled nitric oxide on postoperative renal injury and hemorrhage [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2022, 42(1): 95-100.
[13]	Tian-hao ZHOU, Zhao-chen XIN, Shao-qian DU, Yuan CAO, Jing-xuan XU, Zeng-hong LAO, Hong-xia WANG. Establishment and optimization of co-culture technology for breast cancer organoids [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(8): 1017-1024.
[14]	Yan-jie JI, Hao LUO, Hai-yan CAI, Xin-yu LIU, Shi-jia JIN, Shen-yue SU, Han-zhang XU, Hu LEI, Ying-li WU. Inhibition of CDDO-ME on ubiquitin-specific protease 2a activity and cell proliferation in triple negative breast cancer cells [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(8): 1025-1032.
[15]	Jun-jun ZHOU, Jie ZHAO, Jing-yan TANG, Ma-wei JIANG, Xiu-mei MA, Yong-rui BAI. Analysis of prognostic factors of radiotherapy in children with Ⅲ-Ⅳ neuroblastoma [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(8): 1051-1055.